<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331356</url>
  </required_header>
  <id_info>
    <org_study_id>10/4-T</org_study_id>
    <nct_id>NCT01331356</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia</brief_title>
  <acronym>Impartox</acronym>
  <official_title>Prospective Multicenter Pilot Study Evaluating the Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia According to the Criteria of Rome III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate the analgesic efficacy of botulinum toxin type A in
      refractory chronic proctalgia one month after a bilateral injection of 50 units of Botox ® in
      the ganglion Impar (total dose = 100 units)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in main score (SP) at 1 month</measure>
    <time_frame>one month</time_frame>
    <description>The main objective is to evaluate the analgesic efficacy of botulinum toxin type A in refractory chronic proctalgia one month after a bilateral injection of 50 units of Botox ® in the ganglion Impar (total dose = 100 units) by calculating the main score (SP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the adverse events</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the duration of action of the product (main score SP)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the changing parameters of quality of life: global improvement score / treatment satisfaction assessed by digital scale, international pain scales (MPI, QDSA, QCD) / Beck score and Hospital Anxiety and Depression (HAD) score</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the evolution of analgesics consumption</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Proctalgia</condition>
  <arm_group>
    <arm_group_label>Injection of botulinum toxin type A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia</description>
    <arm_group_label>Injection of botulinum toxin type A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Patient with chronic proctalgia according to the criteria of Rome III

          -  Chronic or recurrent rectal pain

          -  Pains evolve over periods of at least 20 minutes

          -  With the exclusion of other causes of rectal pain: ischemic, inflammatory bowel
             disease, cryptic lesions, intramuscular abscess, anal fissure, hemorrhoids,
             prostatitis and isolated coccydynia

          -  Pains evolve in a regular way since more than 3 months and the symptoms started since
             at least 6 months

          -  These chronic proctalgia include syndromes of anus elevator and nonspecific functional
             anorectal pains

          -  Patient with positive anesthetic block of ganglion Impar (minimum of 30 days before D0
             and maximum of 270 days before D0)

          -  Main score (SP) ≥ 4 before infiltration of botulinum toxin type A

          -  Signed informed consent

          -  Subjects affiliated with an appropriate social security system

        Exclusion Criteria:

          -  Pain related malignancy

          -  Patients with bleeding risk and recent anticoagulant therapy

          -  Surgery within 3 months

          -  Pre-existing anal incontinence

          -  Intolerance of botulinum toxin A, local anesthetics and radio contrast medium

          -  Injection of botulinum toxin in any place whatsoever in the previous 3 months

          -  Pregnancy and breast feeding

          -  Antibiotic treatment by aminoglycosides

          -  Recent anti-inflammatory treatment

          -  Severe myasthenia

          -  Lambert-Eaton syndrome

          -  Patients with neurological disorders, dysphagia, food choking or inhalation pneumonia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Jacques LABAT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>October 4, 2013</last_update_submitted>
  <last_update_submitted_qc>October 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic proctalgia</keyword>
  <keyword>Botulinum toxin type A</keyword>
  <keyword>Ganglion Impar</keyword>
  <keyword>Perineal pain</keyword>
  <keyword>Pudendal neuralgia</keyword>
  <keyword>Refractory chronic proctalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganglion Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

